๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN ยท Real-Time Price ยท USD
60.41
-1.01 (-1.64%)
At close: Nov 20, 2026, 4:00 PM EST
60.41
0.00 (0.00%)
After-hours: Nov 20, 2026, 4:04 PM EST
โ† View all transcripts

UBS Global Biopharma Conference 2026

Nov 16, 2026

Summary

The portfolio combines nine products, 80-country reach and stronger financial performance with growth opportunities from Amicus assets and VOXZOGO. 2027 catalysts include hypochondroplasia review and data from BMN 333 and BMN 440.

Joon Lee
Analyst, UBS

All right. We'll get started. Thank you for joining our UBS Global Biopharma Conference. My name is Joon Lee, one of the biotech analysts at UBS. Here to kick us off is Alexander Hardy, CEO of BioMarin, and Brian, the CFO of BioMarin. Alexander, thank you so much for spending time with us this morning. For the audience who may be new to the story, tell us who BioMarin is today. What have you delivered over the last three years since you joined? Why did you join? Why should investors be excited about what's ahead?

Alexander Hardy
CEO, BioMarin

Well, Joon, thanks very much for having us, and thanks, everybody, for joining for this conversation. That's a lot of questions, but let me just, I suppose, start off with, where are we in our journey? I've been at BioMarin for three years. We've done a lot of stuff during that time. I came to BioMarin because I saw the potential to create an iconic biotech company focused on rare diseases. There are also other large biotech companies, but they are not focused on rare diseases, and there are also mid-size rare disease companies, but they're part of larger enterprises. I saw all the building blocks, and I am convinced that we're on the path to do that. The company, over 25 years, has built a set of capabilities all the way through from research, development, regulatory, manufacturing, commercialization, focused on rare diseases.

An 80-country footprint, which is really amazing, and that's what you need if you're in rare diseases, because you have to go to where the prevalent patient populations are. In many cases, in many of these diseases, the largest patient potential is outside Europe and the U.S., and we have that capability to reach them. We now have nine products. Six of them are first-in-disease treatments. I mean, nine products is really an incredible base. What we've been doing over the last three years is really getting the company operating at scale to create that leadership position. We've dramatically improved the financial performance of the company. Since 2023, we've increased revenue by 60%. Between 2023 and 2025, we've increased earnings per share, doubled it, and cash flow by 5x .

That financial strength has allowed us to really build a really compelling balance sheet, and we've done a lot of transactions. We got GALAFOLD and POMBILITI and OPFOLDA from the Amicus acquisition. In addition, we've done four other pipeline deals that have given us assets all the way through from phase III to phase II to early research. We're now at the stage, we're in 2027, where we start to see a bunch of really exciting clinical catalysts. We have BMN 333, our long-acting CNP. We have first patient data next year. No doubt we're going to talk about that. We have BMN 440 for HPP. We have the first patient data for that. That's a very, very large potential drug.

And then we have, in front of the FDA, we have potentially our seventh first-in-disease treatment, which is VOXZOGO for hypochondroplasia, with a PDUFA date in May. You can see that we've got a fully formed, at-scale rare disease company here, and we've got an exciting growth trajectory, strong financial performance, and now an exciting pipeline as well.

Joon Lee
Analyst, UBS

Excellent. Thanks for-

Alexander Hardy
CEO, BioMarin

I think I answered all your questions. I could be wrong.

Joon Lee
Analyst, UBS

We'll dig into it.

Alexander Hardy
CEO, BioMarin

Okay, good.

Joon Lee
Analyst, UBS

Let's go to the three Ds. We'll start with GALAFOLD and POMBILITI. 3Q was the first full quarter since you acquired Amicus Therapeutics, and both products are performing well. What gets each product to the peak revenues that you laid out in August?

Alexander Hardy
CEO, BioMarin

Yeah. Shall I go ahead? I'll go ahead. We set out, the Amicus Therapeutics acquisition was really a compelling acquisition. Basically, Amicus Therapeutics was a smaller-scale version of BioMarin, but we had more scale, more capabilities, and the ability to really maximize these two assets, GALAFOLD and POMBILITI and OPFOLDA. We have communicated in the second quarter earnings, we communicated what, in our hands, we believe the potential of these products could be. GALAFOLD, we believe we can achieve a peak sales of $1.4 billion.

POMBILITI and OPFOLDA, $1.2 billion. That's because we have that global footprint at a greater scale than Amicus Therapeutics had, and we have a depth of capabilities and the ability to invest to be able to achieve a faster peak and a faster ramp and a higher peak. With GALAFOLD, we believe the opportunity is particularly on the diagnosis side.

There are a lot of patients with the disease of Fabry that are not diagnosed. We think treatment rates can also be increased. We think GALAFOLD is very well positioned there. In the third quarter, we just announced a 13% increase in number of patients treated, which was the first quarter in our hands versus a prior year under Amicus control. That's a really nice level of growth. We're also going to, of course, expand the number of countries as well. We're planning to launch in another 10 countries. Right now, that's our plans. Then POMBILITI and OPFOLDA, the opportunity there really is increasing the switch rate. It's well-positioned there with the evidence, the differentiation. We just, in October, released the PROPEL data, which is the five-year data.

All really shows the benefits of switching from the existing ERTs to POMBILITI and OPFOLDA. We grew patients on therapy in the third quarter by 69%. I think you can already see that we're on a different trajectory, and we're confident in our ability to achieve those higher peak sales. That translates to about 40% higher peak for GALAFOLD and 20% higher peak in POMBILITI and OPFOLDA than Amicus would have achieved.

Joon Lee
Analyst, UBS

Are there any upsides to your base case that you just laid out? What would tell you as we track your progress that you will actually achieve that or exceed that possibly?

Alexander Hardy
CEO, BioMarin

Well, I think GALAFOLD, to go back to the propositions for each product where we think the biggest growth opportunity is, GALAFOLD, it is really that ability to increase the diagnosis rate.

Joon Lee
Analyst, UBS

Yeah.

Alexander Hardy
CEO, BioMarin

In estimating those peak sales in our hands, we did not play with the top of the funnel. We are not assuming the prevalence rate changes.

There is a reasonable possibility, and we are going to certainly look at that. That is one of the capabilities we have, is looking at genotype to phenotype and increasing the understanding of the genetic mutations that are driving the disease. But really, we think that in our hands, GALAFOLD, we can increase the diagnosis rate. Watch the diagnosis rate.

Joon Lee
Analyst, UBS

Got it.

Alexander Hardy
CEO, BioMarin

These are things like family cascade screening, newborn screening. These are the sorts of things that BioMarin does really, really well. Newborn screening is working with governments in most cases to implement systematic newborn screening so that you reduce that level of the diagnostic journey. The typical Fabry patient interacts with 10 different medical specialties before they receive a definitive diagnosis. The opportunity is to shrink that down considerably, and that's the work we're doing. With POMBILITI and OPFOLDA, it's really about that switch rate, so gaining share. Here we are in Europe. There are four countries in Europe where we've already achieved number one market status. We're the number one most prescribed Pompe drug.

Joon Lee
Analyst, UBS

Congratulations.

Alexander Hardy
CEO, BioMarin

That shows what's possible, and watch that as we do that in more and more markets, propelled by the real-world data and the physician experience.

Joon Lee
Analyst, UBS

Great. Brian, how is the Amicus integration progressing on both the synergies and accretion?

Brian Mueller
CFO, BioMarin

Yeah. Thanks, Joon. It's a great question. The revenue opportunity that Alexander described is significant, but the Amicus synergized business, once we fully integrate the companies, really brings substantial earnings and cash flow potential as well. Let me take it three ways briefly, the strategic rationale, the operational design and plan, and now execution. Strategic rationale, as Alexander mentioned, two rare disease assets on the strong part of their commercial revenue growth curve, but operating within what was a smaller-scale company. The promise of bringing these assets that fit hand in glove within BioMarin onto the BioMarin platform, where we are already at scale, not just the 80-country footprint, but all of the capabilities that it takes to commercialize and support these rare disease assets. The promise of a strong combined financial profile was strong from the beginning. Next was the planning and delivery.

Once we dug in post-close and designed the integration plan, again, the model that we were striving for was not just merging two public companies, but how do we bring these two medicines onto the BioMarin operating platform? We designed a plan that called for taking out just about over half of the Amicus operating cost base. Out of about $430 million of non-GAAP operating expenses in calendar 2025, we think we can achieve $220 million of synergies. The integration continues the rest of this year into next year. That's why we reference full year 2028 as the first full year that we will realize the synergies. Again, the combined revenue, growing revenue plus synergized cost profile, we think we can run the Amicus business at about a 60% operating margin by the end of the decade. The last element is delivery and execution.

We've pulled forward some of our targets now twice since we've started the integration. First was our deleveraging target. Originally, we planned to reduce our leverage to 2.5x EBITDA within two years of the acquisition. In the second quarter, we announced that we think we can do that almost a full year earlier, middle of next year. Just in the last Q3 call, we announced that instead of being accretive in the first calendar year post-closing, we think the transaction will be accretive in the first nine months. The teams are doing great. This is a top priority. Of course, there's some complicated longer lead time integration items that will go into next year, but the teams are executing well, and we're delivering on the value.

Joon Lee
Analyst, UBS

It's a real turnaround. Your base business, the metabolic conditions franchise, grew by 44%. What makes this base business, this franchise, durable, and what strategies will you leverage to continue to grow this very important- each business.

Alexander Hardy
CEO, BioMarin

Yeah, the metabolic conditions business unit. Part of our restructuring of BioMarin, we moved into a business unit structure. I mean, when you have got this many products, it is how you manage to attain focus and achieve the potential that the individual products have. In our metabolic conditions business unit, that is where POMBILITI and OPFOLDA and GALAFOLD went into. I think it is one of the things that is underappreciated by investors is actually the growth potential of products which are sort of legacy BioMarin products. The products in that business unit, apart from the two new Amicus products, are ALDURAZYME, NAGLAZYME, VIMIZIM, and BRINEURA. These four products, we continue to grow. The third quarter, all of our BioMarin products added patients around the world.

Even though these products, I mean, I will just take NAGLAZYME and ALDURAZYME, these are long past their primary patent expires, and we are still finding patients around the world. We are still launching them in that 80-country footprint. There are still countries where the regulatory path or the reimbursement path opens. What we said in 2024 is we believe that these products, this is before the Amicus acquisition, could grow at a high single-digit growth rate into the long run. It is pretty cool to see, and it is these capabilities of finding patients, there is still a lot of opportunity to grow for these products.

Joon Lee
Analyst, UBS

What I find impressive about BioMarin and quite different from other companies that it covers your global footprint. How hard has it been to establish that global footprint? You have been doing this for 20 years. I mean, what does that look like from start to finish, establishing your presence in some country that other companies wouldn't dare go into?

Alexander Hardy
CEO, BioMarin

Yeah. It is something really remarkable for a mid-sized company to have this sort of global footprint. In most of those countries, most of those 80 countries, these are BioMarin teams on the ground. I mean, other biotech companies will talk about our global footprint, but it is generally a distributor model.

Joon Lee
Analyst, UBS

Yeah.

Alexander Hardy
CEO, BioMarin

But we believe in rare disease, it's feasible and actually important in many cases to have your own people on the ground. This allows you to share learnings and experience between countries much more effectively. Nobody cares as much as we do about the success of our products, as opposed to a distributor who will have obviously multiple different companies' products within their portfolio. So, it's a source of real pride, but it is also a capability expertise. Rare disease is different, and rare disease in every country is different. So it's one thing to get the regulatory approval, and that represents its own set of challenges, but then the reimbursement and the access, which is totally feasible. Again, 80 countries, we have access. These are paid for by the government, by the public healthcare system in the vast majority of these markets.

These aren't cash pay countries, but you obviously have a very individualized reimbursement. Often, in some cases, it's name patient reimbursement, and you really need to understand the system and have the relationships and the expertise and the reputation to be able to do that.

Joon Lee
Analyst, UBS

Yeah, no, the feedback from the Amicus acquisition was very positive, so kudos to you guys for pulling that trigger at the right time. Perfect timing, by the way, with the patent extension. So, let's move on to VOXZOGO because it is an important product, takes up a disproportionate amount of attention among the investors, but it is generating $1 billion plus in revenue in achondroplasia, and you expect it to continue to grow in 2027 despite the competition from YUVIWEL. So what are the levers for continued growth into next year and beyond?

Alexander Hardy
CEO, BioMarin

Well, there's actually three really important levers for VOXZOGO and the basis of it continuing to grow in 2027. One is the label. So, for several more years, we'll be the only ones with the infant indication, the 0 to 2 or 0 to 3, depending on the competitor population. And why is this important is, this is because this is where the incident population, the majority of our new patient starts on VOXZOGO, and this has been the case for a little while now, in the infant population. All the guidelines, the international guidelines say diagnose and treat in achondroplasia as soon as possible after birth. For example, in the U.S., 60% of babies are actually now diagnosed in utero.

Joon Lee
Analyst, UBS

Yeah.

Alexander Hardy
CEO, BioMarin

And often the treatment decision is made before the baby is even born. So again, we're going to be, for the next several years, the only company with that indication. So it means new patient starts, and the majority will be coming to VOXZOGO. Second is the global footprint we talked about. Important again, and it's fun to be out of the U.S. and talk about this and really resonate where so many companies and so many disease areas are so U.S.-focused. In achondroplasia, 68%, almost 70% of patients are outside United States, Europe, Canada, and Australia. Almost 70% of patients. So we, again, coming back to that global footprint, we're going to continue to grow in that footprint. I mean, it's really remarkable. In the third quarter, we grew patients on VOXZOGO globally, despite competition in the United States, by 17% in the quarter.

So there's a lot more growth globally. We're still launching in countries, we're still penetrating in countries. There's a lot of growth there. And then the third thing is, I've already mentioned, which is really exciting, is new indication. So hypochondroplasia, PDUFA date at the end of May in the United States. We'll also hopefully next year have approvals in Europe and in other important countries around the world. So, that will be the third sort of pillar of growth for VOXZOGO in 2027. So it's going to be an exciting year for VOXZOGO.

Joon Lee
Analyst, UBS

Hypochondroplasia is an exciting new expansion opportunity. Tell us, how big is that market, and how many patients have you been able to identify so far that might be candidates for this once it's approved next May?

Alexander Hardy
CEO, BioMarin

Yeah. I mean, anytime you have a first-in-disease treatment, it is very, very exciting. This is no different in rare disease than other therapy areas. When you have a first-in-disease treatment, you suddenly see the disease area opening up, and physicians and patients have a motivation to get diagnosis and discuss options. We believe that the genetic prevalence is very similar to achondroplasia globally, so about 24,000 patients. But of those, the diagnosis rate is the biggest issue. Again, there has been no approved treatment option. We guide people to think about a total addressable patient population of about 14,000 patients globally. The work that we are doing right now is to increase that diagnosis rate. We have been able to increase that quite significantly so far. Again, when you have the phase III data, that is an important first milestone. Heads go up, people start to think about it.

Now we have the PDUFA date, and our teams are out there in medical affairs doing disease awareness, increasing the diagnosis rate, and identifying a ready patient pool that when the drug is approved, can be candidates for therapy and prosecuted by the sales force. That is the work that is ahead of us. There is a lot of excitement. The obvious advantage that we have is that this is the same treating physician group as achondroplasia.

Joon Lee
Analyst, UBS

Yeah.

Alexander Hardy
CEO, BioMarin

They already know VOXZOGO. They are already comfortable with the safety and efficacy of VOXZOGO. We do not have to build it from scratch like we did with achondroplasia, where there was no single treating or primary treating specialty.

Joon Lee
Analyst, UBS

Yep.

Alexander Hardy
CEO, BioMarin

The pediatric endocrinologists, which we have reached about 1,200 now in the U.S., and done the disease awareness, are going to be the same audience. The other thing that is really cool about it is that the data looks really, really good.

Joon Lee
Analyst, UBS

Exactly.

Alexander Hardy
CEO, BioMarin

I mean, this is on the high end of the scenarios that we were expecting. The efficacy actually looks stronger than achondroplasia, and we have benefits beyond height straight out of the gate, with arm span, as well as obviously you would expect standing height, AGV, and Z-score.

Joon Lee
Analyst, UBS

I was quite impressed that the annualized growth velocity in hypochondroplasia patients were actually better than the achondroplasia patients, because you would think that there is more room for growth in achon patients than in hypocon patients, but maybe hypocon patients respond better? What are thoughts there? Or is it just within margin of error?

Alexander Hardy
CEO, BioMarin

No, no. We were expecting that it was likely to be better.

Joon Lee
Analyst, UBS

Okay.

Alexander Hardy
CEO, BioMarin

That's not how we powered it. We powered the study for the same level of growth as achondroplasia, but we'd seen in the phase II that-

Joon Lee
Analyst, UBS

Yeah

Alexander Hardy
CEO, BioMarin

the Dauber study, that the growth rate was quite significant. I think this gets to the biology and the disease. It seems to be very amenable-

Joon Lee
Analyst, UBS

Yeah

Alexander Hardy
CEO, BioMarin

to CNP. That may not be the case with the other drugs that are coming, the FGFR3s. That's going to be a real question mark as to whether they're. I know you also follow them. As to whether FGFR3s are going to be as effective in hypochondroplasia. It's interesting seeing their dose selection is going up, or their dose is going up in their-

Joon Lee
Analyst, UBS

Yeah

Alexander Hardy
CEO, BioMarin

clinical study.

Joon Lee
Analyst, UBS

Whether you want to be specific and targeted versus you bypass all that and then work downstream or upstream.

Alexander Hardy
CEO, BioMarin

Yeah.

Joon Lee
Analyst, UBS

There is a lot to say about, but that is why you do the experiments and

Alexander Hardy
CEO, BioMarin

Yeah

Joon Lee
Analyst, UBS

you have good data, so congratulations.

Alexander Hardy
CEO, BioMarin

We do.

Joon Lee
Analyst, UBS

But, so we have five minutes left, and we got to talk about some pipeline because you have a lot going on. Why don't we start with BMN 333? It's a long-acting version of VOXZOGO. This will be once a week. It'll be very competitive if it works. So, tell us where you are with this very important program and what we should be expecting next year in terms of data disclosure.

Alexander Hardy
CEO, BioMarin

Yeah. I mean, this is very, very exciting. The potential, we believe, is to have a best-in-class treatment. And we're optimistic with what we've seen. So, we've seen a PK profile which is really compelling. It also exceeded our expectations in the phase I study in healthy volunteers. We saw much, much higher PK levels than our target range versus our competitor's long-acting weekly formulation. So what we're doing is, we've taken it, and the phase II is going extremely well in terms of recruitment, and we will report out the results next year, is we've taken three of the dosages into a phase II, comparing head-to-head against VOXZOGO.

Joon Lee
Analyst, UBS

Yeah.

Alexander Hardy
CEO, BioMarin

And one of the dosages, for example, we achieve 8x the free CNP levels.

Joon Lee
Analyst, UBS

Yeah.

Alexander Hardy
CEO, BioMarin

Then, I'll just say it, Ascendis' TransCon CNP. So 8x the level of free CNP.

Joon Lee
Analyst, UBS

Yeah.

Alexander Hardy
CEO, BioMarin

We believe, from preclinical models, that there's a dose-dependent effect. But this is the experiment. We'll see in patients what 8x the level of free CNP translates to in terms of annualized growth velocity. But we'll go straight then into a phase III. It's a seamless operational design. We'll drop right that into a head-to-head phase III study against VOXZOGO.

Joon Lee
Analyst, UBS

Interesting point. You brought up Ascendis, I'll talk about it. FDA actually

Alexander Hardy
CEO, BioMarin

This is like a court case, isn't it? I entered it into the Okay, so it's free game.

Joon Lee
Analyst, UBS

Interesting, because FDA asked them to do a, I guess, three or four-component studies. They were thinking of doing it, just a combination versus YUVIWEL versus placebo. The FDA asked them to do a human growth hormone alone to make sure that there's a synergy or additive effect.

Alexander Hardy
CEO, BioMarin

Yeah.

Joon Lee
Analyst, UBS

We'll see. I do think it's interesting because I think FDA do also have some questions as to whether they're actually additives, for the FDA to ask them to do that human growth hormone alone arm. We'll see what the data looks like.

Alexander Hardy
CEO, BioMarin

I think that's totally understandable. I mean, that's very predictable that the FDA would have that question. I mean, the FDA has considered growth hormone in achondroplasia and have turned it down up to this point.

Joon Lee
Analyst, UBS

Exactly.

Alexander Hardy
CEO, BioMarin

I would just say, I mean, you're sort of Now you've talked about it, so now I can talk about it.

Joon Lee
Analyst, UBS

You started it.

Alexander Hardy
CEO, BioMarin

I did start it. I don't think any of us are surprised that you see an additive benefit-

Joon Lee
Analyst, UBS

Yeah.

Alexander Hardy
CEO, BioMarin

when you combine.

Joon Lee
Analyst, UBS

Yeah.

Alexander Hardy
CEO, BioMarin

That's really not the question that the clinical community and the patient community. Is that effect going to be durable?

Joon Lee
Analyst, UBS

Yeah.

Alexander Hardy
CEO, BioMarin

You would expect growth hormone to have a short impact in terms of short, that's ironic, an impact on height.

Joon Lee
Analyst, UBS

Yeah.

Alexander Hardy
CEO, BioMarin

Is it going to translate to final adult height? I think you look at the data right now, and as it matures, it looks like the treatment effect is waning.

Joon Lee
Analyst, UBS

Yeah.

Alexander Hardy
CEO, BioMarin

Is the growth hormone causing the growth plates to close sooner? These are all questions that need to be answered. Let's wait for the data and see, but the data needs to speak.

Joon Lee
Analyst, UBS

All right. We want to get through two more drugs quickly. We have two minutes left. The BMN 440 is an oral drug for hypophosphatasia in which STRENSIQ is doing, I guess, really well commercially. It is the only injectable, and you have a pill. Tell us about what we can expect in terms of data 1Q, I believe, 2027 from the phase I/II trial.

Alexander Hardy
CEO, BioMarin

Yeah, we are going to have data next year in 2027. This came from the Alexion acquisition. It is an oral treatment in a marketplace right now, which is really AstraZeneca's STRENSIQ, and then they have their follow-on molecule, which is called ALXN1850. I know you know this, but I am saying it for the audience. This is a lot more exciting than just an oral treatment. I mean, that is compelling in this sort of market. It is a very large market. STRENSIQ sells about $1.7 billion a year. AstraZeneca has communicated that they believe that ALXN1850 market potential is $3 billion-$5 billion. By being the mechanism of action, it works in a different part of the pathway. The ERTs, the enzyme therapies, are bone targeting. We potentially will be able to reach the other morbidities, the muscle pain, muscle weakness associated with the disease.

We think that is really. This is much more exciting than just being an oral therapy.

Joon Lee
Analyst, UBS

Yep.

Alexander Hardy
CEO, BioMarin

This could mean also that we get into the adult onset population, which it looks like ALXN1850, I mean, they had a failed study there. We will have to see what regulators do, but that bone pain-

Joon Lee
Analyst, UBS

Yeah.

Alexander Hardy
CEO, BioMarin

fatigue is a much bigger issue in the adult onset population. We believe this drug has the profile to be able to do that. Important first data in patients next year. It's really exciting. This could be a very big drug if it's successful.

Joon Lee
Analyst, UBS

We actually have 10 minutes after this, so we can go over a couple more minutes to talk about 450, which I think is really exciting. It's a once weekly or once monthly subcu auto-injector for Fabry, for all comers. Tell us about that program and your aspirations. Is this going to be competitive or cannibalizing your existing Fabry program, or is it more synergistic?

Alexander Hardy
CEO, BioMarin

Yeah. This is our most recent deal. This is hot off the press deal we did with two Korean companies for what we call now BMN 450. This potentially could be the first subcutaneous treatment for Fabry disease. We talked about Fabry at the beginning. That's where GALAFOLD is. This is exciting because it's, again, not just the first subcutaneous treatment, but GALAFOLD is limited to about 35%-50% of patients that are amenable from a genetic standpoint. BMN 450 will be able to address the whole market and have definitely a burden of disease, burden of treatment advantage over the current competitors. So it opens up the market for us considerably.

Joon Lee
Analyst, UBS

You are already there, so why not?

Alexander Hardy
CEO, BioMarin

Exactly.

Joon Lee
Analyst, UBS

I think, I have been covering you guys for a while, at prior firm as well as here, and I can tell you the sentiment has really improved over the last year. I am looking forward to your progress this year, and thank you for your time.